Trials / Conditions / Neoplasms, Squamous Cell

Neoplasms, Squamous Cell

14 registered clinical trials studyying Neoplasms, Squamous Cell — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) NCT05797246	National Cancer Institute (NCI)	Phase 2
Recruiting	Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patient NCT05252078	Jiangxi Provincial Cancer Hospital	Phase 2
Terminated	Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions NCT03937791	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198	Christian von Buchwald	N/A
Terminated	PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors NCT03685591	Pfizer	Phase 1
Unknown	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients NCT02526953	Blokhin's Russian Cancer Research Center	Phase 3
Terminated	Safety Study of SEA-CD40 in Cancer Patients NCT02376699	Seagen Inc.	Phase 1
Terminated	Intended Use Study of the BD SurePath Plus™ Pap NCT01234480	Becton, Dickinson and Company	—
Completed	CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial NCT00847912	VA Office of Research and Development	Phase 4
Withdrawn	A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/R NCT01075841	Merck KGaA, Darmstadt, Germany	—
Unknown	Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV NCT01709448	National Institute of Allergy and Infectious Diseases (NIAID)	—
Terminated	Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer NCT00272181	Sesen Bio, Inc.	Phase 2
Terminated	Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and N NCT00412776	Sesen Bio, Inc.	Phase 2 / Phase 3
Completed	IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late NCT00229723	AstraZeneca	Phase 2